Aryl Urea Derivatives as Selective FPRL-1 Receptor Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with the N-formyl peptide receptor like-1 (FPRL-1) receptor modulation are inadequate in effectively addressing inflammatory responses and related diseases due to the receptor's complex role in mediating both anti-inflammatory and pro-inflammatory effects.
Innovation Solution
Development of novel aryl urea derivatives that act as potent and selective modulators of the FPRL-1 receptor, including compounds represented by Formulae I, II, and III, which can function as agonists, antagonists, inverse agonists, partial agonists, or partial antagonists to treat various disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for FPRL-1 receptor modulation, then existing therapeutic approaches are maintained, but they are inadequate in effectively addressing inflammatory responses and related diseases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of FPRL-1 modulators through various substituents (R1-R6 groups including aryl, heterocycle, alkyl, halogen) to optimize receptor binding affinity and selectivity. This structural parameter optimization enables the compounds to effectively address complex inflammatory responses that current treatments cannot handle
Solution Approach 2:
The patent employs composite molecular structures combining aryl urea derivatives with diverse substituent groups to create multi-functional modulators. These composite structures enable simultaneous interaction with multiple receptor domains, providing both anti-inflammatory and pro-resolution effects that current single-function treatments cannot achieve
2Reliability
If novel aryl urea derivatives are developed as FPRL-1 modulators, then potent and selective receptor modulation is achieved, but the complexity of the receptor's dual anti-inflammatory and pro-inflammatory effects remains
Solution Approach 1:
The patent applies local quality by designing specific substituent patterns at different positions (R1-R6) of the aryl urea core structure to target specific receptor domains. For example, particular substitutions at R2-R4 positions enhance anti-inflammatory activity while substitutions at R5-R6 positions modulate pro-resolution effects, allowing selective control over complex receptor signaling
Solution Approach 2:
The aryl urea derivatives act as intermediary molecules that mediate between the complex dual-signaling system of FPRL-1 and therapeutic outcomes. These compounds selectively bind to and modulate specific receptor conformations, translating the complex receptor signaling into controlled anti-inflammatory and pro-resolution responses
3Object-affected harmful factors
If aryl urea derivatives are used to promote anti-inflammatory activities, then tissue damage is reduced, but the need for selective modulation to avoid pro-inflammatory effects increases
Solution Approach 1:
The patent uses parameter changes by optimizing substituent properties (electron-withdrawing/donating groups, steric bulk, hydrophobicity) to fine-tune the balance between anti-inflammatory and pro-inflammatory effects. Specific parameter combinations in R1-R6 groups maximize tissue protection while minimizing pro-inflammatory signaling
Data Source
AI summary
The present invention relates to novel aryl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.